Abnormalities of somatosensory evoked potentials in the quinolinic acid model of Huntington's disease: Evidence that basal ganglia modulate sensory cortical input

Intrastriatal injection of quinolinic acid (QA) in rats provides an animal model that mimics some of the neuropathological and neurochemical alterations observed in the striatum of patients with Huntington's disease (HD). One of the very early neurophysiological signs in HD is a diminution of amplitude of early somatosensory evoked potentials (SEPs) recorded over the parietal cortex. The present study investigated whether the QA model exhibits similar neurophysiological abnormalities. Two weeks after unilateral intrastriatal injection of QA (240 nmol) or of the solvent, early SEPs were recorded with chronically implanted electrodes from the somatosensory cortex or from the ventrobasal nucleus of the thalamus of lightly pentobarbital‐anesthetized rats, in response to single‐shock electrical stimulation of the contralateral forepaw. Whereas intrastriatal injection of solvent did not influence SEPs, the striatal QA lesion significantly reduced the amplitude of early cortical SEPs by about 40% without affecting the latency. SEPs recorded from the ventrobasal nucleus were unchanged after QA lesion. Histological examination and glial fibrillary acid protein staining after intrastriatal injection of QA revealed no evidence for damage in the somatosensory system. It is concluded that (1) the QA animal model of HD mimics some of the SEP abnormalities of patients, and (2) a striatal lesion modulates somatosensory transmission to the cortex in rats.

[1]  S. W. Davies,et al.  No evidence for preservation of somatostatin-containing neurons after intrastriatal injections of quinolinic acid , 1987, Nature.

[2]  R. Dom,et al.  Neuropathology of Huntington's chorea , 1976, Neurology.

[3]  E. Jones,et al.  Retrograde axonal transport and the demonstration of non‐specific projections to the cerebral cortex and striatum from thalamic intralaminar nuclei in the rat, cat and monkey , 1974, The Journal of comparative neurology.

[4]  James E. Vaughn,et al.  GABA neurons are the major cell type of the nucleus reticularis thalami , 1980, Brain Research.

[5]  R. Schwarcz,et al.  Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.

[6]  M. Giordano,et al.  The quinolinic acid model of Huntington's disease: Locomotor abnormalities , 1989, Experimental Neurology.

[7]  C. Darian‐Smith,et al.  Thalamic projections to sensorimotor cortex in the macaque monkey: Use of multiple retrograde fluorescent tracers , 1990, The Journal of comparative neurology.

[8]  R. Schwarcz,et al.  Short- and long-term consequences of intracranial injections of the excitotoxin, quinolinic acid, as evidenced by GFA immunohistochemistry of astrocytes , 1986, Brain Research.

[9]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[10]  G Cheron,et al.  Somatosensory evoked potentials to finger stimulation in healthy octogenarians and in young adults: wave forms, scalp topography and transit times of parietal and frontal components. , 1980, Electroencephalography and clinical neurophysiology.

[11]  J. Penney,et al.  Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. , 1990, The New England journal of medicine.

[12]  M. Herkenham.  The afferent and efferent connections of the ventromedial thalamic nucleus in the rat , 1979, The Journal of comparative neurology.

[13]  T. Lidsky,et al.  Basal ganglia influences on brain stem trigeminal neurons , 1979, Experimental Neurology.

[14]  M. Beal,et al.  Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  O. Jørgensen,et al.  Hippocampal kindling alters the concentration of glial fibrillary acidic protein and other marker proteins in rat brain , 1990, Brain Research.

[16]  Marian DiFiglia,et al.  Excitotoxic injury of the neostriatum: a model for Huntington's disease , 1990, Trends in Neurosciences.

[17]  J. Desmedt,et al.  Nasopharyngeal recordings of somatosensory evoked potentials document the medullary origin of the N18 far-field. , 1991, Electroencephalography and clinical neurophysiology.

[18]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[19]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[20]  J E Skinner,et al.  Selective regulation of thalamic sensory relay nuclei by nucleus reticularis thalami. , 1976, Electroencephalography and clinical neurophysiology.

[21]  G. E. Alexander,et al.  Parallel organization of functionally segregated circuits linking basal ganglia and cortex. , 1986, Annual review of neuroscience.

[22]  D. Fitzpatrick,et al.  Glutamic acid decarboxylase-immunoreactive neurons and horseradish peroxidase-labeled projection neurons in the ventral posterior nucleus of the cat and Galago senegalensis , 1983, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  J. Noth,et al.  Evoked potentials in patients with Huntington's disease and their offspring. I. Somatosensory evoked potentials. , 1984, Electroencephalography and Clinical Neurophysiology.

[24]  E. Favale,et al.  Abnormalities of parietal and prerolandic somatosensory evoked potentials in Huntington's disease. , 1990, Electroencephalography and clinical neurophysiology.

[25]  T. Klockgether.  Excitatory amino acid receptor‐mediated transmission of somatosensory evoked potentials in the rat thalamus. , 1987, The Journal of physiology.

[26]  G. Krauthamer.  Sensory Functions of the Neostriatum , 1979 .

[27]  J. S. Schneider,et al.  A consideration of sensory factors involved in motor functions of the basal ganglia , 1985, Brain Research Reviews.

[28]  G. Oepen,et al.  Visual (VEP) and somatosensory (SSEP) evoked potentials in Huntington's chorea. , 1981, Electroencephalography and clinical neurophysiology.

[29]  E. Favale,et al.  Short-latency somatosensory evoked potentials in degenerative and vascular dementia. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[30]  J. Mazziotta,et al.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.